Emp-Activity: Empagliflozin Functional Capacity

Inclusion Criteria:

• Written informed consent prior to study participation

• Male and female patients ≥ 18 years at Visit 1

• Patients must be contractually capable and mentally able to understand and followthe instructions of the study personnel

• Patients with diagnosis of chronic heart failure NYHA Class 2-4

• Treatment-naïve for SGLT2i at visit 1

• Women of childbearing potential must take appropriate precautions against gettingpregnant according to approval of chosen HF drug(s)

Exclusion Criteria:

• Missing physician's diagnosis of chronic heart failure

• Patients hospitalized at visit 1

• Life expectancy ≤ 12 months according to physician's assessment

• Lack of informed consent

• Pregnant or lactating females

• Participation in a parallel interventional clinical trial

• Chosen treatment with another SGLT2i drug than empagliflozin

• Having been enrolled into the non-empagliflozin-arm of this non-interventional study

• Current or prior treatment with SGLT2i at visit 1

• Patients with contraindications according to current Summary of ProductCharacteristics (SmPC)

• Patients with dependency or relationship to the treating physician